The United States FDA will convene an expert panel to review the seasonal influenza vaccine from Moderna. The agency previously rejected the mRNA-based shot in February but reversed course after discussions with the company. A final approval decision is expected by August 5.

Overcoming the Initial Regulatory Rejection